Daunorubicin Hydrochloride

盐酸柔红霉素

Report date: 2026/03/03 09:48:32
NME

Base Information

Drug NameDaunorubicin Hydrochloride
Drug Alias NameDaunoblastina柔红霉素（正定霉素）的盐酸盐盐酸正定霉素daunorubicina盐酸道诺霉素 +[14] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsBreast NeoplasmsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic +[6] 
Global Approved IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia +[4] 
Approved Indications in ChinaInfections
Original Approved Country/TerritoryUnited States
Original Approved Date1979/12/19
Country/TerritoryCzechiaUnited StatesGermany +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesQingyuan Wuyue Biomedical Co LtdPfizer Corporation Austria Gesellschaft MbhDresden University Of Technology +[5] 
Inactive CompaniesWyeth-AyerstUniversity Of Leicester
Active IndicationsBreast NeoplasmsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL01DB02
Related LinksWikipediaDrugBankKEGG